Tags · Compound
semaglutide
GLP-1 receptor agonist; the compound with the largest published human dataset in this class.
Related in this group: tirzepatide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues
80 topics · page 2 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…
|
+128 | 145 | 3k | 4mo |
|
Splitting a weekly dose in two: the pharmacokinetic argument against
Splitting a weekly dose in two: the pharmacokinetic argument against — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I…
|
+24 | 28 | 51k | 5mo |
|
How the published trials escalated, tabulated side by side
The question in the title: How the published trials escalated, tabulated side by side I will give what I have already checked below so nobody repeats it. A question about technique rather than about dose. I…
|
+4 | 8 | 4.2k | 5mo |
|
The most common factual error about semaglutide on the internet — what changed since
The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 1 ( N…
|
+42 | 46 | 1.7k | 5mo |
|
The lowest dose that does anything: is that a real question?
Asking directly, because I could not find a straight answer: The lowest dose that does anything: is that a real question? I have read the maintained page on this and I still have a gap, so I am asking rather…
|
+100 | 111 | 9.1k | 5mo |
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
2 | 63k | 5mo | |
|
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…
|
2 | 1.9k | 5mo | |
|
Why "dose equivalence" between different incretin analogues is a weak concept
Why "dose equivalence" between different incretin analogues is a weak concept I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this…
|
+124 | 133 | 11k | 5mo |
|
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet ,…
|
2 | 39k | 6mo | |
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version
Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. I would like to understand…
|
+57 | 63 | 1k | 6mo |
|
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
|
+5 | 9 | 21k | 7mo |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA ,…
|
+6 | 10 | 6.1k | 8mo |
|
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still have a…
|
+127 | 137 | 32k | 8mo |
|
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 32k | 8mo | |
|
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A documentation question rather than an analytical one. I have a certificate in front of me that reports a…
|
+86 | 90 | 61k | 9mo |
|
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a certificate in front…
|
+22 | 26 | 1.8k | 9mo |
|
Dose numbers across compounds are not on the same scale
Dose numbers across compounds are not on the same scale — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I am asking…
|
2 | 1.6k | 9mo | |
|
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept Reporting something rather than asking about it, in case the pattern…
|
+7 | 11 | 26k | 9mo |
|
Follow-up: Subcutaneous absorption kinetics and site differences
Subcutaneous absorption kinetics and site differences — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
|
4 | 9.9k | 10mo | |
|
Washout: how long is long enough, and for what purpose
Washout: how long is long enough, and for what purpose — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in…
|
+63 | 70 | 13k | 10mo |
|
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will otherwise…
|
2 | 867 | 10mo | |
|
Escalating every six weeks instead of four: what I observed over eight months — one year on
On the subject in the title: Escalating every six weeks instead of four: what I observed over eight months — one year on Working notes rather than a conclusion. I have read the maintained page on this and I…
|
+55 | 59 | 9.1k | 10mo |
|
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
|
+35 | 39 | 547 | 11mo |
|
Vagal afferents and the gut-brain pathway — one year on
Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…
|
2 | 136 | 11mo | |
|
About the Semaglutide category
GLP-1 receptor agonist. Dosing, published trial data, tolerability, and formulation questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…
|
4 | 4.2k | 11mo | |
|
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
|
+112 | 119 | 3.3k | 11mo |
|
Subcutaneous absorption kinetics and site differences
Posting this under the heading it deserves: Subcutaneous absorption kinetics and site differences Everything below is what sits behind that. I would like to understand what this number means before I repeat…
|
+15 | 19 | 3.9k | 12mo |
|
Holding a dose indefinitely: is there a documented downside?
Holding a dose indefinitely: is there a documented downside? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about technique rather than about dose. I have…
|
+28 | 32 | 57k | 12mo |
|
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
|
2 | 31k | 13mo | |
|
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
|
+5 | 9 | 44k | 13mo |